Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study

BACKGROUND/AIMS: We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL). METHODS: Patients with newly diagnosed ALL, aged ≥ 15 years, were eligible for the study if their leukemic blast cells in bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Dong Won, Park, Han-Seung, Sohn, Sang Kyun, Kim, Dae Young, Kim, Inho, Ahn, Jae-Sook, Do, Young Rok, Lee, Se Ryeon, Eom, Hyeon-Seok, Lee, Won-Sik, Kim, Sung-Hyun, Lee, Ho Sup, Lee, Yoo Jin, Moon, Joon Ho, Lee, Je-Hwan, Party, Adult Acute Lymphoblastic Leukemia Working, Hematology, the Korean Society of
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493456/
https://www.ncbi.nlm.nih.gov/pubmed/37334511
http://dx.doi.org/10.3904/kjim.2022.401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493456/
https://www.ncbi.nlm.nih.gov/pubmed/37334511
http://dx.doi.org/10.3904/kjim.2022.401

Ejemplares similares